Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.
Eli Lilly also forecast annual profit largely above Wall Street estimates on Thursday, saying it expects to earn between $22.50 and $24.00 per share on an adjusted basis this year. Analysts were ...
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback